| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 300% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 05/15/2023 | 300% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 03/28/2023 | 357.14% | B. Riley Securities | → $8 | Initiates Coverage On | → Buy |
| 03/14/2023 | 300% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/15/2023 | 300% | HC Wainwright & Co. | → $7 | Maintains | Buy |
| 11/07/2022 | 300% | HC Wainwright & Co. | $12 → $7 | Maintains | Buy |
| 10/31/2022 | 242.86% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 08/22/2022 | 14.29% | Goldman Sachs | → $2 | Downgrades | Neutral → Sell |
| 05/09/2022 | 585.71% | HC Wainwright & Co. | $15 → $12 | Maintains | Buy |
| 03/14/2022 | 757.14% | HC Wainwright & Co. | $24 → $15 | Maintains | Buy |
| 01/20/2021 | 357.14% | Baird | → $8 | Downgrades | Outperform → Underperform |
| 01/20/2021 | 1271.43% | HC Wainwright & Co. | $16 → $24 | Maintains | Buy |
| 07/14/2020 | 871.43% | BTIG | $31 → $17 | Maintains | Buy |
| 07/26/2019 | 871.43% | Baird | → $17 | Initiates Coverage On | → Outperform |
| 03/15/2019 | 1042.86% | Raymond James | → $20 | Initiates Coverage On | → Outperform |
| 03/07/2019 | 871.43% | HC Wainwright & Co. | → $17 | Initiates Coverage On | → Buy |
| 10/23/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 10/23/2018 | 928.57% | Goldman Sachs | → $18 | Initiates Coverage On | → Neutral |
| 10/23/2018 | 1385.71% | BTIG | → $26 | Initiates Coverage On | → Buy |
| 10/23/2018 | 1328.57% | Barclays | → $25 | Initiates Coverage On | → Overweight |
What is the target price for Gritstone Bio (GRTS)?
The latest price target for Gritstone Bio (NASDAQ: GRTS) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $7.00 expecting GRTS to rise to within 12 months (a possible 300.00% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gritstone Bio (GRTS)?
The latest analyst rating for Gritstone Bio (NASDAQ: GRTS) was provided by HC Wainwright & Co., and Gritstone Bio reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Gritstone Bio (GRTS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gritstone Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gritstone Bio was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
Is the Analyst Rating Gritstone Bio (GRTS) correct?
While ratings are subjective and will change, the latest Gritstone Bio (GRTS) rating was a reiterated with a price target of $0.00 to $7.00. The current price Gritstone Bio (GRTS) is trading at is $1.75, which is within the analyst's predicted range.